Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Suspected or confirmed Methicillin-resistant Staphylococcus aureus (MRSA) infection~* Japanese Male and female patients aged 18 years or above~* Diagnosis of Skin and soft tissue infection with MRSA either suspected or confirmed as the major cause of infection, with/without SSTI (skin and soft tissue infection)-derived MRSA bacteremia suspected~Exclusion Criteria:~* Having received any systemic antibacterial potentially effective against MRSA for \>/=24 hours within 3 days prior to the first infusion of a study drug, or having received/expected to receive the medication within 24 hours prior to the first infusion, unless antibacterial therapy for \>/=72 hours proves to be ineffective on or lack appropriate potency (resistant) to MRSA.~* Moribund clinical condition such as death likely within the first 3 days of a study drug treatment~* History of significant allergy or intolerance to linezolid or BAY1192631~* Known or suspected human immunodeficiency virus (HIV) infection with a CD4+ T-cell count \< 200/μL~* Chronic treatment with immunosuppressive drugs~* Active tuberculosis or non-tuberculous mycobacteriosis which need medical treatments~* Current or anticipated neutropenia with neutrophil count \< 1,000/ mm\^3~* Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) \>/= 8 times the upper limit of reference range OR moderate to severe hepatic disease with Child Pugh score \>/=10.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tedizolid Phosphate (Sivextro, BAY1192631) (Type: EXPERIMENTAL): Participants received 200 mg BAY1192631 solution or tablet once daily (intravenous (I.V.) or oral (PO))
- Linezolid (Type: ACTIVE_COMPARATOR): Participants received 600 mg Linezolid solution or tablet twice daily, every 12 ± 3 hours (intravenous (I.V.) or oral (PO))

Based on this trial design, predict the completion outcome and termination type (if applicable).